This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Due to the lack of efficacy of anti-amyloid treatments in Alzheimer disease (AD), and even though numerous curative and preventive trials are in progress, new risk factors of AD and new potential strategies for prevention and treatment are welcome. Much work needs to be done. If we consider the epidemiologic and clinical studies of the last 2 decades, only 2 risk factors appear really robust and undisputable: age and having the APOE ɛ4 allele. Obviously, no strategies can be proposed to change such factors. In 3 articles appearing in this issue of Neurology®, new risk factors for AD were proposed that involve new pathways and suggest innovative treatment strategies.
In a clinical-based cohort conducted in Southampton, United Kingdom, Holmes et al.1 have shown that raised serum proinflammatory cytokines (tumor necrosis factor–α [TNFα] and interleukin 6 [IL-6]), measured at baseline in patients with mild to moderate AD dementia, were associated with a 2-fold increased frequency of neuropsychiatric symptoms characteristic …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Loss of metal homeostasis may be an additional risk factor for development of Alzheimer disease
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
